



**Department of Vermont Health Access
Pharmacy Benefits Management Program
*DUR Board Meeting Agenda***

May 12, 2020: 6:30 – 8:30 p.m.

- **Executive Session** **6:00 - 6:30**

- **Introductions and Approval of DUR Board Minutes** **6:30 - 6:35**
(Public Comment Prior to Board Action)

- **DVHA Pharmacy Administration Updates** **6:35 - 6:40**

- **Medical Director Update** **6:40 - 6:45**

- **Follow-up Items from Previous Meetings** **6:45 - 6:45**
 - None at this time

- **RetroDUR/ProDUR** **6:45- 7:10**
 - Introduce: PrEP Therapy to Prevent HIV in at-risk Populations
 - Data presentation: Concurrent Use of Opioids and Benzodiazepines
 - Data presentation: Blood Pressure Medication Adherence and Long-term NSAID Use in Chronic Kidney Disease

- **Clinical Update: Drug Reviews** **7:10-7:45**
(Public comment prior to Board action)
 - Biosimilar Drug Reviews**
 - Ziextenzo® (pegfilgrastim-bmez) (Included in the CSF Agents TCR)

 - Full New Drug Reviews**
(Any new drug reviews that also fall within the Therapeutic Class Review (TCR) will be discussed during the Therapeutic Class Review)
 - Annovera® (segesterone acetate & ethinyl estradiol vaginal system) (Included in the Contraceptive Products TCR)
 - Gloperba® (colchicine)
 - Rybelsus® (semaglutide)
 - Slynd® (drospirenone) (Included in the Contraceptive Products TCR)
 - Tovet® foam (clobetasol propionate/emoll)
 - Vumerity® (diroximel fumarate)

- **New Managed Therapeutic Drug Classes** **7:45 -7:45**
(Public comment prior to Board action)
 - None at this time

- **Therapeutic Drug Classes – Periodic Review** **7:45 - 8:30**
(Public comment prior to Board action)
 - Alpha-1 Protease inhibitors
 - Antibiotics: GI & Related
 - Antibiotics: Topical
 - Anti-parasitics
 - Benign Prostatic Hyperplasia (BPH) Agents
 - Contraceptive Products
 - Colony Stimulating Factor Agents
 - Erythropoiesis Stimulating Agents
 - Genital Warts/Actinic Keratosis Therapy
 - Idiopathic Pulmonary Fibrosis
 - Immunosuppressants
 - Movement Disorders
 - Urinary Antispasmodics
 - Vaginal Anti-infectives

- **Review of Newly-Developed/Revised Criteria** **8:00 - 8:30**
(Public comment prior to Board action)
 - None at this time

- **General Announcements** **8:30 – 8:30**

- **Adjourn** **8:30**